Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment
- PMID: 40832110
- PMCID: PMC12358466
- DOI: 10.3389/frdem.2025.1605051
Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment
Abstract
Alzheimer's disease (AD) is characterized by a long preclinical phase lasting more than a decade before the onset of its clinical phase of mild cognitive impairment (MCI) or dementia. Recent advances in psychedelic research underscore numerous neuroplastogenic and anti-inflammatory alterations induced by these compounds, making them promising therapeutic candidates for AD. In this mini review, we will briefly summarize the existing literature using human cerebral organoids to study the molecular and metabolic changes caused by various psychedelic compounds, focusing on their potential therapeutic applications for AD.
Keywords: Alzheimer’s disease; brain organoids; neuroplasticity; psychedelics; stem cells.
Copyright © 2025 Androni, Boyd, Rosenberg and Mahairaki.
Conflict of interest statement
Rosenberg received research grants from the National Institutes of Aging, Alzheimer’s Clinical Trials Consortium, Richman Family Precision Medicine Center of Excellence on Alzheimer’s Disease, Eisai, Functional Neuromodulation, and Lilly; honoraria from Lilly, GLG, Leerink, Medalink, Novo Nordisk, Noble Insights, TwoLabs, Otsuka, MedaCorp, ExpertConnect, HMP Global, Worldwide Clinical Trials, Medscape, and Neurology Week. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2. Cochrane Database Syst Rev. 2017. PMID: 29164603 Free PMC article.
-
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.Alzheimers Dement. 2021 Apr;17(4):704-715. doi: 10.1002/alz.12215. Epub 2021 Jan 21. Alzheimers Dement. 2021. PMID: 33480172 Free PMC article.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.Cochrane Database Syst Rev. 2024 Sep 12;9(9):CD015383. doi: 10.1002/14651858.CD015383.pub2. Cochrane Database Syst Rev. 2024. PMID: 39260823
-
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884. Cochrane Database Syst Rev. 2017. PMID: 29164602 Free PMC article.
References
-
- Aday J. S., Bloesch E. K., Davoli C. C. (2020). Can psychedelic drugs attenuate age-related changes in cognition and affect? J. Cogn. Enhanc. 4, 219–227. doi: 10.1007/s41465-019-00151-6 - DOI
-
- Agüera-Ortiz R., Garc’ıa-Ramos F. J., Grandas P’erez J., L’opez-Álvarez J. M., Montes Rodr’ıguez F. J., Olazar’an Rodr’ıguez J., et al. (2021). Depression in Alzheimer’s disease: a delphi consensus on etiology, risk factors, and clinical management. Front. Psych. 12:638651. doi: 10.3389/fpsyt.2021.638651 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources